International Stem Cell Corp. (ISCO): Moving Ahead with Parkinson’s Disease Program
International Stem Cell Corp., a biotechnology company, is focusing on developing novel stem cell-based therapies and biomedical products. The company recently declared its first quarter results; reporting year-over-year revenue growth of 28% to $1.65 million, with a gross margin of 73%. The revenue was mainly driven by the strong performance of its subsidiary, Lifeline Cell Technology, which contributed around 51% to the company’s total revenue. On April 29, after six month of its trial study, the company reported significant behavioral improvement in its pre-clinical non-human primate (NHP) study of PD. The company spent around $958,000 on research and development (R&D)…